Company news

Rocket Pharmaceuticals, Inc. news in 2019

Rocket Pharmaceuticals, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Rocket Pharmaceuticals Receives the European Medicines Agency PRIME Eligibility for RP-L102 Gene Therapy for Fanconi Anemia

December 15, 2019

Rocket Pharmaceuticals Announces Closing of Public Offering

December 12, 2019

Rocket Pharmaceuticals Prices Public Offering of Common Stock

December 9, 2019

Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I

December 8, 2019

Rocket Pharmaceuticals Presents Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 “Process B” for Fanconi Anemia at 61st American Society of Hematology Annual Meeting

December 7, 2019

Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 “Process B” for Fanconi Anemia

December 5, 2019

Rocket Pharmaceuticals to Host Breakout Session at 61st American Society of Hematology Annual Meeting

December 4, 2019

Rocket Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

November 6, 2019

Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 “Process B” for Fanconi Anemia at the 61st American Society of Hematology Annual Meeting

November 5, 2019

Rocket Pharmaceuticals Announces Participation at the Barclays Gene Editing & Gene Therapy Summit

November 4, 2019

Rocket Pharmaceuticals Presents First Evidence of Long-Term Improvement and Stabilization in Blood Counts and Durable Mosaicism in RP-L102 “Process A” for Fanconi Anemia

October 23, 2019

Rocket Pharmaceuticals Announces Clearance of IND for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency

October 21, 2019

Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress

October 14, 2019

Rocket Pharmaceuticals Announces Participation at the Chardan 3rd Annual Genetic Medicines Conference

September 30, 2019

Rocket Pharmaceuticals Announces IMPD Clearance of RP-L301 Gene Therapy for Pyruvate Kinase Deficiency

September 22, 2019

Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine

September 9, 2019

Decks in 2019